Search research articles
Contact Us
Filters
Showing results (31-40 of 68) with videos related to
Page
of 7
Sort By:
International Journal of Cancer
|
September 30, 2016
mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib
Wenjun Wang, Wei Bai, Enxin Wang, et al.
Digestive Diseases and Sciences
|
July 29, 2025
Irradiation Stents Versus Conventional Stents for Unresectable Malignant Hilar Biliary Obstruction: A Retrospective Study
Menghao Li, Jiang Jin, Jing Niu, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
April 20, 2017
Chemoembolization for Hepatocellular Carcinoma in Patients with Extrahepatic Spread: Prognostic Determinants and Appropriate Candidates
Enxin Wang, Lei Liu, Dongdong Xia, et al.
Radiology
|
July 7, 2017
Association of Nonmalignant Portal Vein Thrombosis and Outcomes after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis
Yong Lv, Chuangye He, Zhengyu Wang, et al.
BMJ Open
|
July 13, 2013
Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial
Xingshun Qi, Chuangye He, Zhanxin Yin, et al.
Scientific Reports
|
February 3, 2016
The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization
Lei Liu, Yan Zhao, Jia Jia, et al.
Hepatology (Baltimore, Md.)
|
March 10, 2022
Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial
Yong Lv, Hui Chen, Bohan Luo, et al.
The FEBS Journal
|
January 16, 2009
Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells
Jie Liang, Fulin Ge, Changcun Guo, et al.
The Lancet. Gastroenterology & Hepatology
|
May 19, 2022
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial
Yong Lv, Hui Chen, Bohan Luo, et al.
The American Journal of Gastroenterology
|
February 25, 2021
Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study
Yong Lv, Wei Bai, Kai Li, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 68) with videos related to
Sort By:
Page
of 7
International Journal of Cancer
|
September 30, 2016
mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib
Wenjun Wang, Wei Bai, Enxin Wang, et al.
Digestive Diseases and Sciences
|
July 29, 2025
Irradiation Stents Versus Conventional Stents for Unresectable Malignant Hilar Biliary Obstruction: A Retrospective Study
Menghao Li, Jiang Jin, Jing Niu, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
April 20, 2017
Chemoembolization for Hepatocellular Carcinoma in Patients with Extrahepatic Spread: Prognostic Determinants and Appropriate Candidates
Enxin Wang, Lei Liu, Dongdong Xia, et al.
Radiology
|
July 7, 2017
Association of Nonmalignant Portal Vein Thrombosis and Outcomes after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis
Yong Lv, Chuangye He, Zhengyu Wang, et al.
BMJ Open
|
July 13, 2013
Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial
Xingshun Qi, Chuangye He, Zhanxin Yin, et al.
Scientific Reports
|
February 3, 2016
The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization
Lei Liu, Yan Zhao, Jia Jia, et al.
Hepatology (Baltimore, Md.)
|
March 10, 2022
Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial
Yong Lv, Hui Chen, Bohan Luo, et al.
The FEBS Journal
|
January 16, 2009
Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells
Jie Liang, Fulin Ge, Changcun Guo, et al.
The Lancet. Gastroenterology & Hepatology
|
May 19, 2022
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial
Yong Lv, Hui Chen, Bohan Luo, et al.
The American Journal of Gastroenterology
|
February 25, 2021
Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study
Yong Lv, Wei Bai, Kai Li, et al.
Page
of 7